Home Latest Articles
Latest Articles
  • Teng-teng PEI, Juan DOU, Ming-hua XU, Jing CHENG, Yuan SHENG, Heng-yu LI
    World Clinical Drug. 2018, 39(6): 389-392.
    Objective

    To analyze the effect of two different treatment regimens of Yanlu Rukang capsule in the patients with cyclomastopathy.

    Methods

    Totally 144 patients with cyclomastopathy were selected and divided into control group and observation group with 72 patients each. The patients in observation group stopped receiving medicine when menstruation came for 1 week and started receiving medicine again after menstruation for 3 weeks. The patients in control group stopped receiving medicine while menstruation came and started receiving medicine at 15 days before menstruation for 2 weeks. All of the patients were treated for three menstrual cycles. The pain alleviating effect was assessed according to the syndrome and follow-up investigation to compare the difference between two medication cycles of the influence on pain alleviating. The changes of breast nodules in two groups after treatment were recorded.

    Results

    After treatment, the score of breast pain in the observation group and the control group were significantly lower than those before treatment (P<0.01), the difference between two groups after treatment was statistically significant (P<0.05); the effective rate of the observation group was 54.17%, the effective rate of the control group was 40.28%, the difference between two groups was statistically significant (P<0.01). In the observation group, 31 cases of breast nodules were narrowed, only 1 case of nodule enlarged. In the control group, 20 cases of breast nodules were narrowed and 5 cases of nodules enlarged, and the difference was statistically significant (P<0.05).

    Conclusion

    Yanlu Rukang capsule used for the treatment of cyclomastopathy through the 3 week treatment regimen after menstruation can improve the pain and reduce the breast nodules of cyclomastopathy patients.

  • Dong-sheng ZHAO, Ke-bo CAI
    World Clinical Drug. 2018, 39(6): 393-397.
    Objective

    To evaluate the short-term clinical efficacy of intravitreal injection of conbercept combined with laser photocoagulation in the treatment of ischemic central retinal vein occlusion.

    Methods

    A total of 50 patients (50 eyes) with ischemic central retinal vein occlusion, who were treated at our hospital from January 2015 to July 2017, were enrolled in this study. All the patients were randomly divided into the control group (25 eyes) and the observation group (25 eyes). The patients in control group were treated with laser photocoagulation alone, and the patients in observation group received the intravitreal injection of conbercept combined with laser photocoagulation. The visual acuity, macular edema and the neovascularization leakage area in two groups were observed. And those before treatment and 3 months after treatment were compared. The adverse drug reactions and repeated treatment were evaluated in two groups.

    Results

    After treatment in observation group, the visual acuity was improved in 18 patients (72.0%) and decreased in 3 patients (12.0%), and another 4 patients (16.0%) had stable vision. In control group, there were 6 patients (24.0%) improved visual acuity, 12 patients (48.0%) decreased visual acuity, and 7 patients (28.0%) had stable vision. The statistical results showed that the patient proportion with improved visual acuity in observation group was significantly higher than that in control group (P<0.05). After treatment, the central macular thickness and neovascularization leakage area were lower than those in control group (P<0.05). Moreover, during the follow-up period, 1 eye (4.0%) in observation group received repeated treatment, which was significantly lower than that in control group (6/24.0%)(P<0.05). In addition, 1 patient in observation group was increased intraocular pressure in the 3 d after injection, and returned to normal after local intraocular treatment. No ocular or systemic adverse drug reactions were observed in other patients.

    Conclusion

    The intravitreal injection of conbercept combined with laser photocoagulation is effective and safe in the treatment of ischemic central retinal vein occlusion, which can promote the absorption of retinal macalar edema, repress neovascularization and improve the vision.

  • Qi ZHAO, Hong-jing ZHU, Guang-ye CHENG
    World Clinical Drug. 2018, 39(6): 398-402.
    Objective

    To investigate the expression of miR-21 and miR-15b in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features and chemotherapy efficacy.

    Methods

    A total of 83 NSCLC patients in our hospital from February 2014 to August 2016 were selected as the research subjects, while 30 healthy volunteers were selected as the control group. All of the patients were treated with cisplatin and gemcitabine. The plasma levels of miR-21 and miR-15b were detected by real-time fluorescence quantitative PCR in patients before and after chemotherapy. The relationships between the expression of miR-21, miR-15b and the clinicopathological features were analyzed. All patients were assigned into disease control group and disease progression group, according to the chemotherapy efficacy. The relationships between miR-21, miR-15b and the chemotherapy efficiency were analyzed.

    Results

    The expression of miR-21 in NSCLC patients was higher than that of the control group (P < 0.05), while the miR-15b was lower than that of the control group (P < 0.05). The expression of miR-21 was higher in the patients with high TNM stage, lymph node metastasis, and smoking history (P < 0.05). The expression of miR-15b was lower in the patients with high TNM stage, adenocarcinoma and lymphnode metastasis (P < 0.05). The expression of miR-21 decreased significantly and the expression of miR-15b increased significantly in the disease control group than those in the disease progression group (P<0.05). The miR-21 and miR-15b were positively correlated with the chemotherapy efficacy (r=0.705, r=0.673, P<0.05).

    Conclusion

    The miR-21 is highly expressed and the miR-15b is lowly expressed in NSCLC patients. The miR-21 and miR-15b are correlated with TNM stage, lymphnode metastasis and chemotherapy efficacy.

  • Xu-qin LI, Jian-hong ZHOU, Ping LI, Xiang LUO, Xiu-qiang MA
    World Clinical Drug. 2018, 39(6): 403-406.
    Objective

    To study the effect of pharmaceutical care on the levels of uric acid (UA), blood glucose, glycosylated hemoglobin (HbA1c) and blood lipid in elderly patients with chronic diseases in community.

    Methods

    A total of 128 elderly patients (aged 60~75 years old) with chronic diseases in 4 communities in Zhenxin were recruited into the study by using cluster sampling. They were divided into two groups, through two stages of pharmaceutical care intervention, and the differences in UA, blood glucose and blood lipids were compared between the patients of the intervention group (n=63) and the control group (n=65).

    Results

    After first phase of the intervention (6 months of intervention), the UA, fasting blood glucose (FBG), HbA1c, triglyceride (TG), total cholesterol (TC), and low density lipoprotein-C (LDL-C) in intervention group were decreased, and high density lipoprotein-C (HDL-C) was increased, which were better than those in control group (P<0.05 or P<0.01). After second phase of intervention (12 months of intervention), the FBG, HbA1c, TG, TC, LDL-C in two groups were decreased, and HDL-C was increased, the differences were statistically significant (P<0.01). However, before and after intervention, the changes of FBG, HbA1c, TC, HDL-C, and LDL-C were statistically significant (P<0.01).

    Conclusion

    Pharmaceutical care can significantly improve the level of blood glucose and blood lipid control in elderly patients with chronic diseases in community.

  • Rui-xia ZHANG, Xue-jun ZHAO, Lin-ling ZHANG, Hai-yan WEN
    World Clinical Drug. 2018, 39(6): 407-411.
    Objective

    To observe the advantage and safety of isobaric 0.5% ropivacaine hydrochloride for the spinal anesthesia (SA) used in preeclampsia cesarean section.

    Methods

    A total of 120 patients with the preeclampsia undergoing cesarean section were randomly divided into two groups as 60 each group. Both groups were punctured in L2-3 interspace, then one group was given SA (SA group) and the other was given continuous epidural anesthesia (CEA group). The patients of SA group received intrathecal isobaric 0.5% ropivacaine hydrochloride 13~14 mg, and the patients of CEA group received 2% liduocaine 4 ml and 0.75% ropivacaine 15~20 ml. The HR and BP were respectively recorded in the following five time points: entering surgery room (T0), skin incision (T1), mean time for fetal delivery (T2), close abdomen (T3) and surgery ending (T4). The anesthesia effect, the sensory and motor block level, the case of general anesthesia, the incidence of adverse drug reactions, the neonatal Apgar score and the umbilical artery blood's pH value were observed.

    Results

    Compared with T0, the BP of two groups at each time point (T1~T4) was decreased in varying degrees (P<0.05). The SBP and its absolute minimum of CEA group were decreased significantly compared with SA group (P<0.05). The maximum sensory and motor block level of SA group was lower than that of CEA group (P<0.05) and SA group had better anesthesia effect than CEA group (P<0.05). The incidence of adverse drug reactions, the Apgar score of the neonate after delivery 1 min, 5 min and the umbilical artery blood's pH value showed no significant difference (P>0.05).

    Conclusion

    The SA with isobaric 0.5% ropivacaine hydrochloride used for preeclampsia cesarean section anesthesia has good advantage and less adverse drug reactions.

  • Hai-yan TAO, Xiao-ping WANG
    World Clinical Drug. 2018, 39(6): 412-416.
    Objective

    To discuss clinical significance of the dynamic changes of serum insulin-like growth factor-1 (IGF-1) level in the patients with acute ischemic stroke (AIS) and relative influence factors.

    Methods

    A total of 60 cases of the patients with cerebral infarction (cerebral infarction group) and 45 cases of the patients with lacunar cerebral infarction (lacunar cerebral infarction group) and 30 health subjects (control group) were enrolled to determine their serum IGF-1 level within 3 days after onset and on 2 weeks by chemiluminescence method. The relative influence factors of serum IGF-1 level were analyzed. The ADL and mRS score of 3 months after treatment were followed up, and the correlation between serum IGF-1 level and prognosis was analyzed.

    Results

    The serum IGF-1 level within 3 days after onset in cerebral infarction group and lacunar cerebral infarction group was significantly lower than that in control group (P<0.01), and the serum IGF-1 level in cerebral infarction group was lower than that in lacunar cerebral infarction group (P<0.01). The logistic regression analysis showed that 2 h postprandial plasma glucose (2hPG) was an independent influence factor of IGF-1 level (P<0.05). The IGF-1 level in the good prognosis group was significantly higher than that in the poor prognosis group (P<0.01).

    Conclusion

    Serum IGF-1 level can help to identify the severity and prognosis of AIS patients. It has potential clinical significance for AIS treatment. The 2hPG may be an independent influence factor to IGF-1 level.

  • Wen-qi XU, Sheng WANG, Yan WANG, Qi-bing MEI, Li LIU
    World Clinical Drug. 2018, 39(6): 417-421.

    Normal intestinal microbiota is involved in many important physiological processes such as the nutrient metabolism, immune regulation and nervous system development. However, the change of genes and environmental factors can cause intestinal microecological imbalances, which can lead to a variety of physiological activity disorders including obesity development and related metabolic syndromes. The obesity patients have a higher risk of suffering from diabetes, cardiovascular disease, and cancer. In the past, the cognition of obesity mainly revolved around the mechanism of fat metabolism. However, the reversal of intestinal microbiota dysbiosis can effectively improve obesity and related metabolic diseases. Now, the mechanism of intestinal microbiota disorder affected obesity development is still not very clear. This article aims to review the research progress on the mechanism of intestinal microbiota disorder in obesity development, to provide a reference for obesity improvement.

  • Yu-wen XU, Ya-li WENG
    World Clinical Drug. 2018, 39(6): 422-426.

    Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The recent research states that the clinical burden of NAFLD is not only increasing the morbidity and mortality associated with liver disease, but also affecting extra-hepatic organs, such as cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This review describes NAFLD and its associated extra-hepatic organ diseases such as T2DM, CVD, and CKD.

  • Na ZHAO, Li-hui CHEN, Yu-zhu ZHANG, Guang-tao XIA
    World Clinical Drug. 2018, 39(6): 427-430.

    Connective tissue disease (CTD) complicated with interstitial lung disease (ILD) is the important causes of CTD patients' death. However, the clinical diagnosis and treatment of connective tissue disease related interstitial lung disease (CTD-ILD) are still difficult. The systemic sclerosis associated interstitial lung disease (SSc-ILD) is a common CTD-ILD with a high incidence. This article gives a brief overview of the clinical features, diagnosis and treatment of CTD-ILD, as well as the clinical study of anti fibrosis drug therapy for SSc-ILD.

  • Qing-wei LI, Zheng LU
    World Clinical Drug. 2018, 39(5): 289-292.

    The American academy of sleep medicine (AASM) issued the clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults in 2016. Based on this guideline and some existing reviews, this article gives an interpretation on the insomnia drug therapy of 14 drugs.

News